Alliance's Oxygent back on track for cardiac surgery:
This article was originally published in Clinica
Executive Summary
Following a setback in January, Alliance Pharmaceutical is once again pushing ahead with plans to develop its oxygen-carrying therapeutic, Oxygent, for use during cardiac surgery. The company had suspended enrolment in a phase III trial of the product in heart bypass procedures after observing an unexpected difference in the incidence of adverse events (AEs) between the treated patients and controls (see Clinica No 942, p 19). A preliminary analysis of the safety data has failed to find evidence to link the product directly to imbalance in AEs, says the San Diego, California company.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.